Articles On Imugene (ASX:IMU)

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The ASX he...

Small caps have gained for a sixth straight day, even as their larger peers declined. The Small Ordinaries index of Australia’s 101st to 300th biggest companies finished the week up 6.7 points, or 0.2 per cent, to a fresh 13-year high of 3,...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest movers – the winners and losers alike. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday t...

07 Apr 2021 - $620 million cancer treatment provider Imugene (ASX:IMU) has announced that an independent team of researchers have certified that lung cancer drug PD1-Vaxx is safe f…

Imugene (ASX:IMU) shares have hit an all-time high after the Sydney biotech company announced its cancer vaccine was continuing to show early promise in a small clinical trial. A cohort review committee has allowed the Phase 1 trial to move...

The Imugene Limited (ASX: IMU) share price is through the roof today, breaking record highs. At the time of writing, shares in the medical research and development company are up 11.5%, trading at a record high of 14.5 cents each. By compa...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Source: Enjoy The Life, Shutterstock Summary ASX 200 increased 0.8% on Friday, however it edged lower Monday morning with a decline of almost 33% following the quarterly rebalance announcement. ASX 200 saw 6 new companies being added...

The Imugene Limited (ASX: IMU) share price is on the move today. This comes after the company announced an update on its Phase 1 clinical trial of its immunotherapy candidate, PD1-Vaxx. PD1-Vaxx is a B-cell immunotherapy designed to treat...

The company is a clinical-stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.

The Imugene Limited (ASX: IMU) share price is on the rise today. This comes after the company received a successful outcome from the Cohort Review Committee (CRC) regarding its PD1-Vaxx immunotherapy. PD1-Vaxx is a B-cell immunotherapy des...

The CRC unanimously agreed that PD1-Vaxx is safe with no dose-limiting toxicities (DLTs) and has recommended to proceed to the next dose escalation due to safety and tolerability.

Summary Chimeric Therapeutics commenced trading on the ASX today following the successful completion of its IPO. The drug development company raised almost A$35 million from Institutional as well as sophisticated investors. The Compan...

Summary Imugene Limited (ASX:IMU) has completed the recruitment of patients under its ongoing HER-Vaxx Phase 2 clinical trial. Imugene has reduced the overall number of patients under Phase 2 trial to 36 following the IDMC guidance. T...

Imugene Ltd [ASX:IMU] certainly finished 2020 with a bang. With a 5% lift in the IMU share price this morning, the stock is making waves once more. Today, it has since eased back from those record highs, but it is still faring well... The p...

Imugene Limited (ASX: IMU) shares have jumped by 5% in trading so far today after the biotechnology company announced it has completed recruitment for its HER-Vaxx Phase-2 gastric cancer trial. At the time of writing, the Imugene share pri...

ShareCafeAustralia…One Hour In…ASX up 85 points ASX200 up 85 points (1.3%) to 6692. Market tracking better on prospects for more US stimulus after the Democrats won control of the Senate.  Disturbingly,  the focus this morning has been on t...

The Phase 2 trial represents a clinical proof-of-concept for HER-Vaxx to indicate that B-cell activating immunotherapy platform can induce clinically active antibody responses.

The Rhythm Biosciences Ltd (ASX:RHY) share price has rocketed over 640% for the past twelve-month period. From the beginning of November alone, the share price has soared over 355%.  For the past few weeks, we’ve been watching Rhythm Biosc...

Summary Imugene Limited (ASX:IMU) completes the enrolment of three patients under the first cohort under PD1-Vaxx Phase I clinical trial. Following the Phase I trial, a monotherapy optimal biological dose will be determined through a r...

The clinical-stage immune-oncology company has enrolled the first three patients in the first low dose PD1-Vaxx cohort with non-small cell lung cancer.

Summary Imugene Limited (ASX:IMU) has received an R&D tax refund of ~$4.82 million under government’s R&D tax incentive. The tax incentive is expected to support Imugene in its commercial and clinical milestones. Imugene has r...

Receiving the $4,823,466 million in additional funding will further support the company's commercial and clinical milestones.

Bell Potter has raised its valuation of Imugene to 17 cents from 5 cents and has maintained its buy (speculative) recommendation.

Summary Imugene Limited (ASX:IMU) has dosed its first patient in PD1-Vaxx Phase 1 trial in Melbourne. An optimal biological dose as a monotherapy will be determined after review by Imugene’s Cohort Review Committee. Imugene intends to...

Sydney biotech company Imugene (ASX:IMU) says it has dosed its first patient with its drug candidate PD1-Vaxx, a checkpoint immunotherapy ... Read More The post First patient dosed with Imugene’s lung cancer drug candidate appeared first on...

ShareCafeAustralia…One Hour In…ASX up 33 points ASX200 up 33 points (0.5%) to 6551. AUB (-1.6%); will acquire 360 Underwriting Solutions for $127m. Collins Foods (+4.2%); 1H profit +15%.   Strong result. Domino’s Pizza (+11%); Investor Day...

The first-in-human, Phase 1, multi-centre, dose-escalation study of PD1-Vaxx is recruiting patients with non-small cell lung cancer.

Summary Imugene Limited (ASX:IMU) has recently shared promising interim data from its continuing Phase 2 trial of HER-Vaxx. The interim analysis results demonstrated that twice as many patients survived on the HER-Vaxx plus SOC chemoth...

The share price of biotechnology company Imugene Limited (ASX: IMU) has been on a tear this year. Imugene shares are up another 13% today at the time of writing, meaning the share price has soared over 300% in the year to date. With a marke...

The Imugene Ltd [ASX:IMU] share price is trading 15% higher at time of writing. Rising on the back of new news from the biotech’s phase 2 trial. In what is now just the latest leg up for the company in the past month... The post Imugene Sha...

The IDMC provided guidance that it is scientifically and ethically appropriate to reduce the overall number of patients required to complete the study, given the strong signal observed in the data.

Summary Imugene has received the US FDA IND approval to kick-start Phase 1 clinical trial of PD1-Vaxx in the US. The FDA approval enables Imugene to commence patient dosing and recruitment in its Phase 1 clinical trial in the US in non-...

ShareCafeAustralia…One Hour In…ASX Up 6 Points ASX200 up 6 points (0.1%) to 5933. – AMP (+8.6%); says the Ares takeover proposal implies a value of $1.85 a share. Trading @ $1.65.– IAG (-0.8%); CEO Mark Milliner to leave. Nick Hawkins new C...

US FDA approval of the IND allows Imugene to initiate patient recruitment and dosing in its USA Phase I clinical study in non-small cell lung cancer (NSCLC) patients.

ul> Post delivering a solid performance in the June 2020 quarter, Imugene Limited (ASX:IMU) has released another set of robust quarterly results for the September 2020 quarter. During the quarter, Imugene achieved several significant...

During the September quarter, the clinical-stage immuno-oncology company continued to progress clinical programs and remains well-funded to cater for an expected increase in expenditures.

The company is well-funded to deliver on commercial and clinical milestones including the development of CF33, PD1-Vaxx and HER-Vaxx treatments.

Summary Imugene has attained a core patent in the largest pharmaceutical market of the world. The patent protects its cancer growth factor immunotherapy platform, predominantly unique combination treatments that target members of the IG...

Imugene's oncolytic viruses are designed to infect, replicate in, and kill cancer cells, leaving healthy cells essentially unharmed.

02 Oct 2020 - Immuno-oncology company, Imugene (ASX:IMU) has been granted a patent from the US United States Patent and Trademark Office which it says protects its cancer growth fa…

The company recently boosted its balance sheet with a $5.7 million underwriting agreement to support four continuing clinical programs - CF33, PD1, Vaxx and HER-Vaxx as well as provide funding for IP and milestone payments.

Summary Imugene has appointed Dr Rita Laeufle as its new Chief Medical Officer and a member of its executive leadership team. Dr Laeufle will lead the Company’s global clinical development, medical monitoring, and regulatory activities....

The company recently entered into an agreement to underwrite outstanding listed options which provides holders with an option to purchase shares in the company at 2.6 cents per share.

NSW-headquartered clinical stage immuno-oncology firm, Imugene Limited (ASX:IMU) has secured an underwriting agreement with Bell Potter Securities Limited with institutional investors to underwrite the balance of options not exercised by 30...